BioAuxilium Research launches new THUNDER TR-FRET biomarker assay kits and an enhanced assay development service
The new technology hopes to meet customer demand for high-performing, reliable yet affordable immunoassays
28 Feb 2023
At the 2023 Society for Laboratory Automation and Screening (SLAS) international conference and exhibition in San Diego, BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully validated assay kits to the biomedical research community, has announced the expansion of its no-wash THUNDER™ time-resolved Förster resonance energy transfer (TR-FRET) technology portfolio by introducing six new biomarker research assay kits, a reader control kit, and an enhanced assay development service for drug discovery research.
BioAuxilium developed the new biomarker assays in response to customer requests for reliable cell-based assays that provide an alternative to expensive immunoassay platforms such as other TR‑FRET and bead-based assay technologies. The new offerings include a panel of six key mouse inflammatory cytokines (CCL-2/MCP1, IFN-beta, IFN-gamma, IL-2, IL-6, and TNF-alpha), expanding the company’s portfolio to a total of 100 cell-based assay kits (76 Cell Signaling Kinases, 23 Biomarkers, and a cAMP Assay). The ready-to-use reader control kit allows users to assess in just 10 minutes the suitability of TR‑FRET compatible microplate readers to perform europium-based TR-FRET measurements.
The new assay development service offers three types of custom assay solutions: labeling of antibodies with proprietary TR-FRET fluorophores, custom assay development services, and custom kit development services. These comprehensive, yet flexible custom solutions are designed to fast-track assay development, while further reducing risk, turnaround time, and cost.
THUNDER TR-FRET technology from BioAuxilium is a robust, proprietary platform based on a FRET pair showing an enhanced spectral compatibility and TR-FRET signal, best antibody pairs selected specifically for TR-FRET, and a panel of optimized lysis and assay buffers. In addition, the 'add-incubate-read' protocol of the immunoassay platform, combined with its full compatibility with different TR-FRET readers, facilitates streamlined workflows and automation for high-throughput screening. All THUNDER TR-FRET assays are extensively validated to ensure specificity, sensitivity, reproducibility, and lot-to-lot consistency.